283. Acquired pure red cell aplasia Clinical trials / Disease details
Clinical trials : 19 / Drugs : 36 - (DrugBank : 23) / Drug target genes : 20 - Drug target pathways : 102
Showing 1 to 3 of 3 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00314795 (ClinicalTrials.gov) | April 6, 2006 | 13/4/2006 | Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease Efficacy and Safety of Peginesatide(AF37702) in the Treatment of Anemia in Participants With Chronic ... | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of ... | Anemia;Chronic Kidney Disease;Chronic Renal Failure;Pure Red Cell Aplasia | Drug: Peginesatide | Takeda | NULL | Completed | 18 Years | N/A | All | 22 | Phase 2 | France;Germany;United Kingdom |
| 2 | EUCTR2005-004944-30-DE (EUCTR) | 08/03/2006 | 20/12/2005 | A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia. | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematide™) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematide™) in the T ... | Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease Med ... | Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other ... | Takeda Development Centre Europe Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Germany;United Kingdom | ||
| 3 | EUCTR2005-004944-30-GB (EUCTR) | 23/02/2006 | 09/12/2005 | A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia. | An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of ... | Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease Med ... | Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other descriptive name: Hematide, peginesatide Product Name: AF37702 Injection Product Code: AF37702, Hematide INN or Proposed INN: peginesatide Other ... | Takeda Development Centre Europe Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ... | Germany;United Kingdom |